Methotrexate is a key component of the treatment of inflammatory rheumatic diseases and
the mainstay of therapy in rheumatoid arthritis. Hepatotoxicity has long been a concern for …

Background We aim to evaluate the efficacy and tolerability of Janus kinase inhibitors (JAKi)
as monotherapy and in combination with methotrexate (MTX) in active rheumatoid arthritis …

Background Regulatory T cells (Tregs) have been found to play crucial roles in immune
tolerance. However, the status of Tregs in refractory rheumatoid arthritis (RA) is still unclear …

Abstract Treat-to-target (T2T) is currently the most fashionable strategy for treatment-naïve,
early rheumatoid arthritis (RA) patients. A T2T approach can lead to a complete and drug …

Background There is growing evidence from case reports that methotrexate (MTX) therapy
may impair bone metabolism in individual patients leading to low bone mass, atraumatic …

Rheumatoid arthritis (RA) is characterized by inflammation outbreak and joint destruction. As
the main culprit of RA, neutrophils firstly migrated to inflamed joints and aggravate …

Objectives To estimate prevalence rates and identify baseline predictors of adverse events
(AEs) over the first year of treatment in patients with RA starting MTX. Methods Data came …

Background In the management of rheumatoid arthritis (RA), there is a clinical need to
identify which patients are at high-risk of not responding to methotrexate (MTX), or …

Objectives In rheumatology, there is a clinical need to identify patients at high risk (> 50%) of
not responding to the first-line therapy methotrexate (MTX) due to lack of disease control or …

Background Methotrexate (MTX) is a systemic therapy largely used for moderate‐severe
psoriasis. There is a lack of data on its use in daily practice and particularly on its long‐term …